Advertisement
Advertisement
TARS
Tarsus Pharmaceuticals, Inc. Common Stock
62.26
USDSponsored
-1.22
-1.92%
May 22, 16:00 UTC -4
Closed
Pre-Market
62.57
+0.31
+0.50%
TARS Earnings Reports
Positive Surprise Ratio
TARS beat 16 of 23 last estimates.
70%
Next Report
Date of Next Report
Aug 04, 2026
Estimate for Q2 26 (Revenue/ EPS)
$170.71M
/-$0.26
Implied change from Q1 26 (Revenue/ EPS)
+17.42%
/+62.50%
Implied change from Q2 25 (Revenue/ EPS)
+66.28%
/-45.83%
Tarsus Pharmaceuticals, Inc. Common Stock earnings per share and revenue
On May 06, 2026, TARS reported earnings of -0.16 USD per share (EPS) for Q1 26, beating the estimate of -0.37 USD, resulting in a 57.65% surprise. Revenue reached 145.39 million, compared to an expected 150.67 million, with a -3.51% difference. The market reacted with a -1.24% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 7 analysts forecast an EPS of -0.26 USD, with revenue projected to reach 170.71 million USD, implying an increase of 62.50% EPS, and increase of 17.42% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Belite Bio, Inc - ADR
Report Date
May 20, 2026 For Q1 26
Estimate
-$0.64
Actual
-$0.68
Surprise
-4.87%
Immunovant, Inc. Common Stock
Report Date
May 20, 2026 For Q4 26
Estimate
-$0.61
Actual
-$0.73
Surprise
-19.11%
Roivant Sciences Ltd. Common Shares
Report Date
May 20, 2026 For Q4 26
Estimate
-$0.35
Actual
-$0.57
Surprise
-64.63%
Compugen Ltd
Report Date
May 18, 2026 For Q1 26
Estimate
-$0.07
Actual
-$0.08
Surprise
-8.11%
Connect Biopharma Holdings Limited Ordinary Shares
Report Date
May 22, 2026 For Q1 26
Estimate
-$1.53
Actual
-$2.35
Surprise
-53.05%
Scilex Holding Company Common Stock
Report Date
May 20, 2026 For Q1 26
Estimate
-Actual
-$4.76
Surprise
-
MiNK Therapeutics, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.78
Actual
-$0.56
Surprise
+27.43%
OS Therapies Incorporated
Report Date
May 18, 2026 For Q1 26
Estimate
-$0.18
Actual
-$0.27
Surprise
-49.83%
Annovis Bio, Inc.
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.40
Actual
-$0.63
Surprise
-56.37%
Akari Therapeutics plc ADR (0.01 USD)
Report Date
May 19, 2026 For Q1 26
Estimate
-$1.40
Actual
-$1.57
Surprise
-11.81%
FAQ
What were Tarsus Pharmaceuticals, Inc. Common Stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Tarsus Pharmaceuticals, Inc. Common Stock reported EPS of -$0.16, beating estimates by 57.65%, and revenue of $145.39M, -3.51% below expectations.
How did the market react to Tarsus Pharmaceuticals, Inc. Common Stock's Q1 2026 earnings?
The stock price moved down -1.24%, changed from $64.76 before the earnings release to $63.96 the day after.
When is Tarsus Pharmaceuticals, Inc. Common Stock expected to report next?
The next earning report is scheduled for Aug 04, 2026.
What are the forecasts for Tarsus Pharmaceuticals, Inc. Common Stock's next earnings report?
Based on 7
analysts, Tarsus Pharmaceuticals, Inc. Common Stock is expected to report EPS of -$0.26 and revenue of $170.71M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement